Search Results - Thomas Thisted

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics by F. Donelson Smith, Robert H. Pierce, Thomas Thisted, Edward H. van der Horst

    Published in Antibodies (2023-08-01)
    Get full text
    Article


  2. 2

    The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats by Paul R. Pentel, Michael D. Raleigh, Mark G. LeSage, Thomas Thisted, Stephen Horrigan, Zuzana Biesova, Matthew W. Kalnik

    Published in BMC Biotechnology (2018-07-01)
    Get full text
    Article


  3. 3

    Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model by Gaëlle H. Martin, Alexis Gonon, Perrine Martin-Jeantet, Florence Renart-Depontieu, Zuzana Biesova, Anokhi Cifuentes, Arnab Mukherjee, Thomas Thisted, Astrid Doerner, Dean O. Campbell, Ludovic Bourré, Edward H. van der Horst, Amélie Rezza, Kader Thiam

    Published in Frontiers in Immunology (2024-02-01)
    Get full text
    Article


  4. 4

    VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response by Thomas Thisted, F. Donelson Smith, Arnab Mukherjee, Yuliya Kleschenko, Feng Feng, Zhi-Gang Jiang, Timothy Eitas, Kanam Malhotra, Zuzana Biesova, Adejumoke Onumajuru, Faith Finley, Anokhi Cifuentes, Guolin Zhang, Gaëlle H. Martin, Yoshiko Takeuchi, Kader Thiam, Robert D. Schreiber, Edward H. van der Horst

    Published in Nature Communications (2024-04-01)
    Get full text
    Article


Search Tools: